| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, Research & Experimental |
| Manuscript Type |
Prospective Study |
| Article Title |
Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Nathalie Talbodec, Pauline Le Roy, Peggy Fournier, Benoit Lesage, Elodie Lepoutre, François Castex, Jean Michel Godchaux, Lionel Vandeville, Benjamin Bismuth, Xavier Lesage, Pauline Bayart, Michael Genin, Christel Rousseaux, Veronique Maquet, Salvatore Modica, Pierre Desreumaux and Caroline Valibouze |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Caroline Valibouze, MD, PhD, Doctor, Doctor, Department of Digestive Surgery and Transplantation, Lille University, Rue Michel Polonovski, Lille 59037, France. caroline_valibouze@hotmail.fr |
| Key Words |
Chitin-glucan; Irritable bowel syndrome; Abdominal pain; Flatulence; Defecatory disorders; Stool consistency; Natural non-pharmacological treatment |
| Core Tip |
Irritable bowel syndrome is a common functional gastrointestinal disorder characterized by recurrent abdominal pain associated with altered bowel habits. Treatment options are limited and often inadequate, which leads to dissatisfaction among patients receiving standard medical care. Our study showed that 4 weeks of daily treatment with GASTRAP® DIRECT, a class IIa medical formulation containing a combination of chitin-glucan and simethicone, is well tolerated and rapidly effective in reducing abdominal pain, bloating, abdominal distension, and flatulence with an improvement of stool consistency and defecatory disorders. |
| Publish Date |
2024-05-27 07:09 |
| Citation |
Talbodec N, Le Roy P, Fournier P, Lesage B, Lepoutre E, Castex F, Godchaux JM, Vandeville L, Bismuth B, Lesage X, Bayart P, Genin M, Rousseaux C, Maquet V, Modica S, Desreumaux P, Valibouze C. Efficacy and tolerability of chitin-glucan combined with simethicone (GASTRAP® DIRECT) in irritable bowel syndrome: A prospective, open-label, multicenter study. World J Gastrointest Pharmacol Ther 2024; 15(3): 90757
|
| URL |
https://www.wjgnet.com/2150-5349/full/v15/i3/90757.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v15.i3.90757 |
